Prostate cancer: link between androgen deprivation therapy and dementia


A new analysis of patients who have undergone treatment for prostate cancer shows a connection between androgen deprivation therapy ( ADT ), a testosterone-lowering therapy and a common treatment for the disease, and dementia, according to researchers from the Perelman School of Medicine at the University of Pennsylvania.

Previous studies have shown men who undergo ADT may be at an increased risk of dementia, including Alzheimer's disease, compared to men who were not treated with the therapy. This new analysis, the largest of its kind ever performed on this topic, shows that all existing studies taken together support the link to dementia and show a possible link to Alzheimer's.

The findings are published in Prostate Cancer and Prostatic Diseases.

Researchers compiled data from four different global databases looking at studies on ADT patients and dementia and Alzheimer's.

An analysis of more than 50,000 patients worldwide showed a consistent statistical link between men who underwent ADT for prostate cancer and men who developed dementia.
The numbers have shown correlation, not causation at this point, but that there is evidence of a direct connection.

Research has shown androgens play a key role in neuron maintenance and growth, so the longer you undergo this therapy to decrease androgens, the more it may impact the brain's normal functions.

The analysis was less conclusive on the question of Alzheimer's. While there was still a connection, it was not as clearly defined as the link to dementia.

Evidence for a link between androgen deprivation therapy and neurocognitive dysfunction is growing. ( Xagena )

Source: University of Pennsylvania, 2017

XagenaMedicine_2017



Indietro

Altri articoli

Castration-resistant prostate cancer ( CRPC ) is defined as disease progression during ADT ( androgen deprivation therapy ), with serum...


The phase III SPARTAN study evaluated Apalutamide ( Erleada ) vs Placebo in patients with non-metastatic castration-resistant prostate cancer (...


Lynparza ( Olaparib ) has been approved in the European Union ( EU ) for patients with metastatic castration-resistant prostate...


The European Commission ( EC ) has granted marketing authorisation for the expanded use of Erleada ( Apalutamide ) to...


SPARTAN has evaluated Apalutamide ( Erleada ) versus placebo in patients with nonmetastatic castration-resistant prostate cancer ( nmCRPC ) and...


Darolutamide ( Nubeqa ) is a structurally distinct androgen receptor inhibitor with a favorable safety profile, approved for treating men...


Tthe phase III IPATential150 study met its co-primary endpoint of radiographic progression-free survival ( rPFS ) in patients with metastatic...


The European Commission ( EC ) has granted marketing authorisation for Erleada ( Apalutamide ), a next generation oral androgen...


Results from the phase 3 TITAN study were presented in an oral session at the American Society of Clinical...


For patients with prostate cancer, treating the disease with androgen deprivation therapy ( ADT ) is linked to a...